Data generated by the investigators in this program project grant and others indicate that gamma-secretase inhibitors (GSIs) may be useful drugs in such diverse settings Alzheimer's Disease (AD), cancer, multiple sclerosis, and immune rejection, and that the adverse effects caused by GSIs are not insurmountable. We will use GSIs as tools to explore the therapeutic potential of targeting gamma-secretase in vivo. In the context of this program project the main goal of the chemistry core will be to synthesize sufficient GSI to support the studies in Projects 1-3 and develop methods to measure GSI levels in body fluids and tissues following in vivo dosing.
The aims of the Chemistry Core are:
Aim 1. To synthesize all four L-alanine-containing enatiomerically pure diastereomers of LY-411,575, an extremely potent gamma-secretase inhibitor (GSI), and to isolate large quantities of the most potent diastereomer of LY-411,575 for in vivo studies.
Aim 2. To develop a reliable method of qualitative and quantitative analysis of LY-411,575 stereoisomers and related analytes and metabolites in biological fluids and tissues.
Aim 3. To synthesize other GSIs required for the studies proposed in projects 1-3.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG025531-05
Application #
8098932
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
2013-06-30
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
5
Fiscal Year
2010
Total Cost
$119,050
Indirect Cost
Name
University of Massachusetts Amherst
Department
Type
DUNS #
153926712
City
Amherst
State
MA
Country
United States
Zip Code
01003
Ran, Yong; Cruz, Pedro E; Ladd, Thomas B et al. (2014) ?-Secretase processing and effects of ?-secretase inhibitors and modulators on long A? peptides in cells. J Biol Chem 289:3276-87
Zhang, Shubing; Chung, Wen-cheng; Miele, Lucio et al. (2014) Targeting Met and Notch in the Lfng-deficient, Met-amplified triple-negative breast cancer. Cancer Biol Ther 15:633-42
Roderick, Justine E; Gonzalez-Perez, Gabriela; Kuksin, Christina Arieta et al. (2013) Therapeutic targeting of NOTCH signaling ameliorates immune-mediated bone marrow failure of aplastic anemia. J Exp Med 210:1311-29
Espinoza, Ingrid; Miele, Lucio (2013) Notch inhibitors for cancer treatment. Pharmacol Ther 139:95-110
Golde, Todd E; Koo, Edward H; Felsenstein, Kevin M et al. (2013) ?-Secretase inhibitors and modulators. Biochim Biophys Acta 1828:2898-907
Espinoza, Ingrid; Miele, Lucio (2013) Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett 341:41-5
Chakrabarty, Paramita; Tianbai, Li; Herring, Amanda et al. (2012) Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition. Mol Neurodegener 7:36
Das, Pritam; Verbeeck, Christophe; Minter, Lisa et al. (2012) Transient pharmacologic lowering of Aýý production prior to deposition results in sustained reduction of amyloid plaque pathology. Mol Neurodegener 7:39
Minter, Lisa M; Osborne, Barbara A (2012) Canonical and non-canonical Notch signaling in CD4? T cells. Curr Top Microbiol Immunol 360:99-114
Cho, Sungpil; Lu, Meiling; He, Xiaolong et al. (2011) Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells. Proc Natl Acad Sci U S A 108:20778-83

Showing the most recent 10 out of 32 publications